Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Kappos, Ludwig; Gold, Ralf; Miller, David; MacManus, David; Havrdova, Eva; Limmroth, Volker; Polman, Chris; Schmierer, Klaus; Yousry, Tarek; Yang, Minhua; ERAKSOY, Mefküre; Meluzinova, Eva; Rektor, Ivan; Dawson, Katherine; Sandrock, Alfred; O'Neill, Gilmore

doi:10.1016/s0140-6736(08)61619-0

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Kappos L., Gold R., Miller D. H., MacManus D. G., Havrdova E., Limmroth V., ...Daha Fazla

LANCET, cilt.372, sa.9648, ss.1463-1472, 2008 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 372 Sayı: 9648
Basım Tarihi: 2008
Doi Numarası: 10.1016/s0140-6736(08)61619-0
Dergi Adı: LANCET
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1463-1472
İstanbul Üniversitesi Adresli: Hayır

Özet

Background Oral fumarate (BG00012) might have dual anti-inflammatory and neuroprotective effects. Our aim was to assess the efficacy and safety of BG00012 in patients with relapsing-remitting multiple sclerosis.